Company: ARVN
Filing Date: 2025-05-01
Form Type: 8-K
Source: 0001655759-25-000081
Chunk: 4

Company: ARVINAS, INC.
Filing Date: 2025-05-01
Form: 8-K
Item: Item 9.01
Chunk 4
---
 future clinical trials; the Company's ability to obtain, maintain, and protect intellectual property rights related to its product candidates; the Company's ability to manage expenses and to raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “ Risk Factors” section in the Company’s most recent Annual Report on Form 10-K filed with the U. S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors, in the Company’s most recent filings with the U. S. Securities and Exchange Commission. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                         ARVINAS, INC.                               
  Date: May 1, 2025      By:                /s/ Andrew Saik          
                                            Andrew Saik